Accelerate Diagnostics (NASDAQ:AXDX) Stock Price Crosses Below 200-Day Moving Average of $1.11

Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Get Rating) shares crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.11 and traded as low as $0.49. Accelerate Diagnostics shares last traded at $0.53, with a volume of 349,583 shares changing hands.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research note on Friday, February 17th.

Accelerate Diagnostics Trading Up 5.2 %

The firm has a 50 day moving average price of $0.64 and a 200-day moving average price of $1.11. The firm has a market cap of $43.23 million, a PE ratio of -0.55 and a beta of 1.12.

Hedge Funds Weigh In On Accelerate Diagnostics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Swiss National Bank lifted its stake in Accelerate Diagnostics by 19.0% during the first quarter. Swiss National Bank now owns 85,300 shares of the medical research company’s stock worth $123,000 after purchasing an additional 13,600 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Accelerate Diagnostics by 17.9% during the first quarter. JPMorgan Chase & Co. now owns 418,359 shares of the medical research company’s stock worth $602,000 after purchasing an additional 63,513 shares during the last quarter. HighTower Advisors LLC lifted its stake in Accelerate Diagnostics by 115.6% during the first quarter. HighTower Advisors LLC now owns 37,302 shares of the medical research company’s stock worth $53,000 after purchasing an additional 20,000 shares during the last quarter. Bank of Montreal Can purchased a new stake in Accelerate Diagnostics during the first quarter worth approximately $27,000. Finally, Baird Financial Group Inc. lifted its stake in Accelerate Diagnostics by 15.5% during the first quarter. Baird Financial Group Inc. now owns 1,741,547 shares of the medical research company’s stock worth $2,508,000 after purchasing an additional 233,478 shares during the last quarter. Hedge funds and other institutional investors own 33.14% of the company’s stock.

Accelerate Diagnostics Company Profile

(Get Rating)

Accelerate Diagnostics, Inc is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens.